TrialHaematologica2020

Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial.

Jin-Hua Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.